Actinium Pharmaceuticals (ATNM) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ATNM shares.
View ATNM analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12 month target prices for Actinium Pharmaceuticals' shares. Their ATNM share price forecasts range from $11.60 to $50.00. On average, they predict the company's share price to reach $28.32 in the next year. This suggests a possible upside of 378.4% from the stock's current price.
View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts.

Actinium Pharmaceuticals' stock was trading at $10.65 on January 1st, 2023. Since then, ATNM stock has decreased by 44.4% and is now trading at $5.92.
View the best growth stocks for 2023 here.

Actinium Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totaling 1,950,000 shares, a decline of 5.3% from the August 31st total of 2,060,000 shares. Based on an average trading volume of 166,400 shares, the short-interest ratio is currently 11.7 days.
View Actinium Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ATNM earnings forecast.

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) announced its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.08.

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATNM stock can currently be purchased for approximately $5.92.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $159.84 million and generates $1.03 million in revenue each year. The biotechnology company earns $-33,020,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for the company is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at investorrelations@actiniumpharma.com.